Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Status Completed

Clinical Trial Summary

This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.

It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning.

Clinical Trial Description

This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of Dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.

Flexible dosing to a maximum of 40 mg per day will be used. It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning. Blood cytokine levels will also be measured at weeks 0, 12, and 24 to determine their relationship to depressive symptoms and improvement. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Dysthymic Disorder

Clinical Trial Details

NCT number	NCT00220701
Study type	Interventional
Source	St. Luke's-Roosevelt Hospital Center
Contact
Status	Completed
Phase	Phase 4
Start date	June 2002
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01583400` - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial	N/A
Recruiting	`NCT00260390` - Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial	Phase 4
Completed	`NCT00518986` - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression	Phase 4
Completed	`NCT04437485` - eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk	Phase 2
Completed	`NCT01892124` - Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms	N/A
Active, not recruiting	`NCT01473615` - Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression	N/A
Completed	`NCT01542957` - Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention	N/A
Completed	`NCT00619411` - Interpersonal Psychotherapy for Depressed Adolescents and Parents	Phase 1
Completed	`NCT00225251` - Wellbutrin XL for Dysthymic Disorder	Phase 4
Recruiting	`NCT03507114` - Rumination Focus Cognitive Behavior Therapy	N/A
Recruiting	`NCT03917550` - RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression	N/A
Completed	`NCT00688818` - Quetiapine in Co-Morbid Depressive and Anxiety Disorders	N/A
Completed	`NCT00096642` - Cognitive Behavioral Therapy for Early-Onset Depression	N/A
Completed	`NCT02458690` - eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients	Phase 2
Completed	`NCT00883519` - The Efficacy of Parent Involvement in the Treatment of Adolescent Depression	Phase 1/Phase 2
Completed	`NCT01852383` - Duloxetine Treatment in Elderly With Dysthymia	Phase 4
Completed	`NCT01561105` - Improving Depression Care for Elders: Coordinating Center	N/A
Not yet recruiting	`NCT05118594` - Testing a Precision Psychotherapy System for Low-income Patients	N/A
Completed	`NCT01537068` - Desvenlafaxine vs. Placebo Treatment of Chronic Depression	Phase 4
Completed	`NCT00073359` - Effects of Therapist Behavior on the Treatment of Depressed Adolescents	Phase 1/Phase 2